Randomized double-blind 2 X 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women

Journal of Clinical Oncology

Volumn 27, Issue 23, 2009, Pages 3749-3756

  Decensi, Andrea ^a   Robertson, Chris ^a   Guerrieri Gonzaga, Aliana ^a   Serrano, Davide ^a   Cazzaniga, Massimiliano ^a   Mora, Serena ^a   Gulisano, Marcella ^a   Johansson, Harriet ^a   Galimberti, Viviana ^a   Cassano, Enrico ^a   Moroni, Simona M ^a   Formelli, Franca ^a   Lien, Ernst A ^a   Pelosi, Giuseppe ^a   Johnson, Karen A ^a   Bonanni, Bernardo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; PLACEBO; SOMATOMEDIN C; TAMOXIFEN; 4 HYDROXYNORTAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RETINOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN BINDING PROTEIN 3; TUMOR MARKER;

ADD ON THERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER PREVENTION; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; HAZARD RATIO; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; INTRADUCTAL CARCINOMA; LOW DRUG DOSE; MAMMOGRAPHY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OPTIC NEURITIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THICKNESS; UTERUS; BLOOD; DRUG ADMINISTRATION; DRUG POTENTIATION; INCIDENCE; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK; TREATMENT OUTCOME;

ADULT; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FENRETINIDE; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MAMMOGRAPHY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VITAMIN A;

EID: 68949092354     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.3797     Document Type: Article

References (43)

1. Gail MH, Costantino JP, Bryant J, et al: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846, 1999
2. Veronesi U, Mariani L, Decensi A, et al: Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17:1065-1071, 2006
3. Ratko TA, Detrisac CJ, Dinger NM, et al: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49:4472-4476, 1989
4. Conley B, O'Shaughnessy J, Prindiville S, et al: Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 18:275-283, 2000
5. Singletary SE, Atkinson EN, Hoque A, et al: Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8:2835-2842, 2002
6. Zujewski J, Pai L, Wakefield L, et al: Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res Treat 57:277-283, 1999
7. Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998
8. Schernhammer ES, Holly JM, Pollak MN, et al: Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:699-704, 2005
9. Toniolo P, Bruning PF, Akhmedkhanov A, et al: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828-832, 2000
10. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al: Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90:1461-1467, 1998
11. Torrisi R, Pensa F, Orengo MA, et al: The synthetic retinoid fenretinide lowers plasma insulinlike growth factor I levels in breast cancer patients. Cancer Res 53:4769-4771, 1993
12. Torrisi R, Parodi S, Fontana V, et al: Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int J Cancer 76:787-790, 1998
13. Decensi A, Veronesi U, Miceli R, et al: Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 9:4722-4729, 2003
14. Boyd NF, Byng JW, Jong RA, et al: Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87:670-675, 1995
15. Boyd NF, Guo H, Martin LJ, et al: Mammographic density and the risk and detection of breast cancer. N Engl J Med 356:227-236, 2007
16. Byrne C, Schairer C, Wolfe J, et al: Mammographic features and breast cancer risk: Effects with time, age, and menopause status. J Natl Cancer Inst 87:1622-1629, 1995
17. Cuzick J, Warwick J, Pinney E, et al: Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621-628, 2004
18. Decensi A, Robertson C, Viale G, et al: A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779-790, 2003
19. Cohen I, Perel E, Tepper R, et al: Dosedependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients. Breast Cancer Res Treat 53:255-262, 1999
20. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651, 1995
21. Guerrieri-Gonzaga A, Robertson C, Bonanni B, et al: Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 24:129-135, 2006
22. Hilditch JR, Lewis J, Peter A, et al: A menopause-specific quality of life questionnaire: Development and psychometric properties. Maturitas 24:161-175, 1996
23. Formelli F, Clerici M, Campa T, et al: Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11:2036-2042, 1993
24. Gjerde J, Kisanga ER, Hauglid M, et al: Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatographytandem mass spectrometry. J Chromatogr A 1082: 6-14, 2005
25. Decensi A, Bonanni B, Baglietto L, et al: A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res 10:4389-4397, 2004
26. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007
27. Colleoni M, Viale G, Zahrieh D, et al: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 10:6622-6628, 2004
28. Pickles T, Agranovich A, Berthelet E, et al: Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94:362-367, 2002
29. Yates RA, Dowsett M, Fisher GV, et al: Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73:543-548, 1996
30. Diorio C, Pollak M, Byrne C, et al: Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14:1065-1073, 2005
31. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, et al: Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336-2343, 2004
32. Torrisi R, Parodi S, Fontana V, et al: Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients. Cancer Epidemiol Biomarkers Prev 3:507-510, 1994
33. Decensi A, Torrisi R, Polizzi A, et al: Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst 86:105-110, 1994
34. Andrews WJ, Winnett G, Rehman F, et al: Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production. J Steroid Biochem Mol Biol 94:159-165, 2005
35. Ciolino HP, Wang TT: Sathyamoorthy N: Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxyphenyl)-retinamide. Br J Cancer 83:333-337, 2000
36. Broaddus RR, Xie S, Hsu CJ, et al: The chemopreventive agents 4-HPR and DFMO inhibit growth and induce apoptosis in uterine leiomyomas. Am J Obstet Gynecol 190:686-692, 2004
37. Sabichi AL, Hendricks DT, Bober MA, et al: Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 90:597-605, 1998
38. Veronesi U, Maisonneuve P, Rotmensz N, et al: Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99:727-737, 2007
39. Camerini T, Mariani L, De Palo G, et al: Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 19:1664-1670, 2001
40. Pollack IF, DaRosso RC, Robertson PL, et al: A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 3:1109-1115, 1997
41. Trump DL, Smith DC, Ellis PG, et al: High-dose oral tamoxifen, a potential multidrug-resistancereversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811-1816, 1992
42. Menard S, Camerini T, Mariani L, et al: Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 93:240-241, 2001
43. Pellegrini R, Mariotti A, Tagliabue E, et al: Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 6:863-869, 1995